BPA
ALXO icon

Beacon Pointe Advisors’s ALX Oncology ALXO Stock Holding History

Beacon Pointe Advisors’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$25.1K Buy
+12,500
New +$23.8K ﹤0.01% 1819

Other funds holding ALXO

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

Beacon Pointe Advisors's ALXO Position: Q1 2026 in Review

Beacon Pointe Advisors opened a new position in ALX Oncology (ALXO) in Q1 2026: 12,500 shares worth $25.1K. The stake represents ﹤0.01% of the portfolio and ranks #1819 among its holdings.

69 funds tracked by Wall St. Rank hold ALXO as of Q1 2026.

  • Beacon Pointe Advisors held 12,500 shares of ALX Oncology worth $25.1K as of Q1 2026.
  • ALX Oncology was a new Beacon Pointe Advisors position in Q1 2026.
  • ALX Oncology made up ﹤0.01% of Beacon Pointe Advisors's portfolio in Q1 2026, its #1819 holding.
  • 69 funds tracked by Wall St. Rank held ALX Oncology as of Q1 2026.

Based on Beacon Pointe Advisors's 13F filing for Q1 2026, filed 15 May 2026.